271 results on '"Le Pavec, Jérôme"'
Search Results
52. Transplantation for Pulmonary Arterial Hypertension with Congenital Heart Disease: Impact of current therapeutic approach including a high-priority allocation programme on outcomes
53. Determinants of survival after lung transplantation in telomerase-related gene mutation carriers: A retrospective cohort
54. Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure
55. Scleroderma Lung Disease
56. Risk of Lung Allograft Dysfunction Associated With Aspergillus Infection
57. Lung transplantation for sarcoidosis: outcome and prognostic factors
58. Can radiation-recall predict long lasting response to immune checkpoint inhibitors?
59. Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’
60. Pulmonary hypertension in pulmonary Langerhans’ cell histiocytosis
61. Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders
62. Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension: Clinical Characteristics and Impact of Pulmonary Arterial Hypertension Therapies
63. Airway complications in lung transplant recipients with telomere‐related interstitial lung disease.
64. Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies
65. The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study
66. Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial Hypertension
67. Systemic Sclerosis-associated Pulmonary Arterial Hypertension
68. Impact of donor, recipient and matching on survival after high emergency lung transplantation in France
69. Pregnancy after lung and heart–lung transplantation: a French multicentre retrospective study of 39 pregnancies
70. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
71. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
72. Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation
73. Portopulmonary Hypertension: Survival and Prognostic Factors
74. Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension
75. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases
76. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19
77. Combined lung transplantation and percutaneous septal defect closure for end-stage atrial septal defect associated pulmonary arterial hypertension
78. The 2016-2019 ImmunoTOX Assessment Board Report: Results from a Descriptive Real-Life Study of a Collaborative Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors
79. Heart-lung transplantation: current indications, prognosis and specific considerations
80. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis
81. Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension
82. Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
83. Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension
84. Prescription difficile d’un traitement anticoagulant au cours du syndrome de Hughes-Stovin sévère
85. De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome
86. Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy
87. Consortium de détection et prise en charge des atteintes pulmonaires induites par la bléomycine
88. Lymphoproliferative Disorders after Lung Transplantation: Clinicopathological Characterization of 16 Cases with Identification of Very-Late-Onset Forms
89. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group
90. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
91. Pulmonary Arterial Hypertension Associated With Pulmonary Langerhans Cell Histiocytosis: Impact Of Pulmonary Hypertension Therapy
92. Hypertension artérielle pulmonaire et sclérodermie systémique : les pièges
93. Renal Dysfunction In Patients With Scleroderma-associated Pulmonary Arterial Hypertension: Severity And Impact On Outcomes
94. Characteristics And Survival Of African-American Patients With Pulmonary Hypertension Associated With Scleroderma
95. Impact Of Pulmonary Arterial Hypertension Specific Therapy On Portopulmonary Hypertension
96. Combined Pulmonary Hypertension (PH) And Interstitial Lung Disease In Systemic Sclerosis: The Role Of PH Therapy
97. Scleroderma Lung Disease
98. Portopulmonary Hypertension
99. Pulmonary Veno-Occlusive Disease
100. Centres de référence “maladies rares respiratoires”
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.